At INTERCEPT, we are transforming the landscape of Crohn’s disease research by shifting from reactive symptom management to proactive early detection and prevention. Our groundbreaking approach leverages biomarkers - measurable substances found in body fluids that can signal the presence of the earliest stages of the disease before it clinically manifests - to identify individuals at risk before symptoms develop, enabling timely and effective interventions that could stop the disease before it starts.
WebsiteNetwork detailsCatalogueINTERCEPT prospective
INTERCEPT prospective
Description
General Design
- Type
- Cohort study
- Cohort type
- Clinical cohort
- Data collection type
- Prospective
- Start/End data collection
- not available
Networks
Part of networks